涩里番

Symposium on the implementation of precision medicine in healthcare

Estonia is a global pioneer in the digitalization of public services, including healthcare. Their biobank is a pillar of their strategy, with 200,000 participants, or about 20% of their adult population recruited. We will discuss some of the innovative tools and platforms that have been developed in Estonia to facilitate the implementation of precision medicine and the return of results to their population.

Call for proposals: Foundational and Research in Motion

D2R is pleased to launch the call for proposals for the Foundational and Research in Motion funding program.

This program integrates two previously separate funding programs - Foundational Projects and Research in Motion (RIM) - into a single, unified call. This program provides researchers with the flexibility to explore novel ideas and develop cutting-edge solutions that have the potential to lead to commercialization or clinical application.

D2R awards $10 million to accelerate RNA-based therapies for rare diseases and cancer

Montreal, March 26, 2025 鈥� 涩里番鈥檚 DNA to RNA Initiative (D2R) has awarded over $10 million in funding to support three groundbreaking research projects that will advance RNA-based therapies for cancer and rare genetic diseases. The awards were initially announced at the D2R Research Symposium on March 13, 2025.

涩里番 awards $500,000 to accelerate Mpox research and vaccine development

Montreal, February 13, 2025 鈥� 涩里番鈥檚 DNA to RNA Initiative (D2R) and 涩里番 Interdisciplinary Initiative in Infection and Immunity (MI4) have awarded $500,000 to fund five high-impact research projects aimed at advancing the understanding of Mpox through its Rapid Response for Mpox Research funding program.

D2R awards over $6 million to support Core Platforms

The D2R (DNA to RNA) Initiative has awarded more than $6 million to support eight Core Platforms at 涩里番 and one at the University of British Columbia through its Core Platform Sustainability funding program. This program supports state-of-the-art Core Platforms that are essential for advancing research and development and facilitating technology uptake and transfer in fields relevant to RNA therapeutics.

Remembering Emil Skamene (1941鈥�2024), pioneer in genetic research at 涩里番聽

It is with deep sadness that we remember Emil Skamene, a pioneer in genetic research at 涩里番.聽 His groundbreaking work on host genetic susceptibility to infections has shaped the field for over three decades. Skamene鈥檚 legacy continues to inspire scientists, including D2R鈥檚 Chief Scientific Officer, Philippe Gros, who, alongside Professor聽Erwin Schurr, honors him in a heartfelt eulogy published in Nature Genetics.

D2R announces new round of funding, investing $1.5 million to advance research in RNA therapeutics and to support 涩里番 Centres and Institutes

Montreal 鈥� December 19, 2024聽鈥� The D2R (DNA to RNA) Initiative is proud to announce the recipients of its latest round of funding, awarding a total of $1.5 million to four principal investigators and five 涩里番 Centres and Institutes. These awards are designed at advancing research in RNA therapeutics by facilitating industry collaboration and supporting the next generation of scientific leaders as well as research Centres and Institutes.

Research | A new trial hopes to use mRNA to halt the devastating progression of Creutzfeldt-Jakob Disease

Prion diseases came to public attention during the 1980s and 鈥�90s, when Mad Cow Disease was in the news. While transmission to humans from infected beef has largely been eliminated, other forms of these devastating diseases are unfortunately still around, like Creutzfeld-Jacob Disease (CJD). In fact, according to the US Centers for Disease Control, cases of CJD have been on the rise in the last two decades.

Event | Seminar, The power of first impressions: Using viral imprinting for broadly reactive vaccine development | Dec 11, 2024

The Emerging Topics in Health (EToH) seminar series is cohosted by the Departments of Microbiology and Immunology, Physiology and Human Genetics, the Goodman Cancer Institute (GCI), the 涩里番 Research Centre on Complex Traits (MRCCT), and M[i]4. The organizers invite guest speakers to talk about their current research.聽This seminar series is part of the Current Topics & Seminars course and is open for attendance by MIMM students and all interested individuals.

CQDM partners with D2R to enhance collaborations among researchers and industry in RNA research

Montr茅al, November 28th 鈥� CQDM is proud to announce a strategic partnership with the D2R (DNA to RNA) Initiative at 涩里番, aimed at funding translational research projects carried out through collaborations between researchers and industry. This alliance seeks to support and accelerate the development and commercialization of innovative RNA-based therapies.

Event | Workshop in Precision Health and Medicine | January 9, 2025

Synergizing our strengths in new technologies in omics, digital sciences, and translational medicine to advance patient care.

Event | MI4 6th Annual Scientific Symposium | December 4, 2024

Join MI4 for the 6th Annual Scientific Symposium on Wednesday, December 4, 2024, from 11:30 PM to 5:30 PM at the 涩里番 Faculty Club. This year鈥檚 theme, "Microbiome: Decoding the Invisible World," promises an engaging lineup, including a keynote by Prof. Yasmine Belkaid, President of Institut Pasteur. Don鈥檛 miss this chance to hear groundbreaking insights from leading experts in the MI4 community.

Event | Practical examples of research in indigenous context | November 20, 2024

D2R partner, Tahatikonhsont贸ntie' Quebec Network Environment for Indigenous Health Research, is organizing a webinar "Practical examples of research in Indigenous context" on November 20 from 12-1:30pm.聽

Guest speakers include:聽

Event | Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder | November 14, 2024

Dear Colleagues,

Please see the next Medical Genetics Grand Rounds scheduled talk below:

Philippe Gros appointed Chief Scientific Officer of D2R

Philippe Gros has been appointed Chief Scientific Officer (CSO) of 涩里番鈥檚 DNA to RNA (D2R) Initiative, effective September 30, 2024. Prior to this role, he served as Deputy Vice-President (Research and Innovation) at 涩里番. This appointment follows a thorough international search, with the selection committee enthusiastic about their recommendation.